540501-04-0

Usage

General Description

2-Amino-4-chloro-5-iodo-benzoic acid is a chemical compound with the molecular formula C7H5ClINO2. It is a derivative of benzoic acid, containing both amino, chloro, and iodo functional groups. 2-AMino-4-chloro-5-iodo-benzoic acid is commonly used in the pharmaceutical industry for the synthesis of various drugs and is also a valuable intermediate in organic synthesis. Its unique combination of substituents makes it a versatile building block for the production of a wide range of pharmaceuticals and other chemical compounds. Additionally, the presence of both amino and halogen groups in its structure makes 2-amino-4-chloro-5-iodo-benzoic acid a valuable tool for studying and manipulating biological systems and chemical reactions.

Upstream product

• 89-77-0 2-Amino-4-chlorobenzoic acid 
• 199850-56-1 methyl 2-amino-4-chloro-5-iodobenzoate 

Downstream Products

• 1450618-75-3 7-chloro-2-ethyl-6-iodo-3-phenethylquinazolin-4(3H)-one 
• 1450618-61-7 (2E)-3-(7-chloro-2-ethyl-3,4-dihydro-4-oxo-3-phenethylquinazolin-6-yl)-N-hydroxyacrylamide 

Relevant academic research and scientific papers

QUINAZOLINE DERIVATIVES USEFUL AS SELECTIVE HDAC6 INHIBITORS

Provided herein is a compound of Formula (I): or a pharmaceutically acceptable salt thereof, wherein the variables are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) and methods of using the compo

Quinazolin-4-one derivatives as selective histone deacetylase-6 inhibitors for the treatment of Alzheimer's disease

Novel quinazolin-4-one derivatives containing a hydroxamic acid moiety were designed and synthesized. All compounds were subjected to histone deacetylase (HDAC) enzymatic assays to identify selective HDAC6 inhibitors with nanomolar IC50 values. (E)-3-(2-Ethyl-7-fluoro-4-oxo-3-phenethyl-3,4- dihydroquinazolin-6-yl)-N-hydroxyacrylamide, 4b, is the most potent HDAC6 inhibitor (IC50, 8 nM). In vitro, these compounds induced neurite outgrowth accompanied by growth-associated protein 43 expression, and they enhanced the synaptic activities of PC12 and SH-SY5Y neuronal cells without producing toxic or mitogenic effects. Several of the compounds dramatically increased nonhistone protein acetylation, specifically of α-tubulin. Some of the more potent HDAC6 inhibitors decreased zinc-mediated β-amyloid aggregation in vitro. N-Hydroxy-3-(2-methyl-4-oxo-3-phenethyl-3,4-dihydro- quinazolin-7-yl)-acrylamide, 3f, the most promising drug candidate, selectively inhibits HDAC6 (IC50, 29 nM), practically does not affect human ether-a-go-go-related membrane channel activity (IC50 >10 μM) or cytochrome P450 activity (IC50 >6.5 μM) in vitro, and significantly improves learning-based performances of mice with β-amyloid-induced hippocampal lesions.

BENZIMIDAZOLE QUINOLINONES AND USES THEREOF

Methods of inhibiting various enzymes and treating various conditions are provided that include administering to a subject a compound of Structure I or IB, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer. Compounds having the Structure I and IB have the following structures and have the variables described herein. Such compounds may be used to prepare medicaments for use in inhibiting various enzymes and for use in treating conditions mediated by such enzymes.